WO2004037293A1 - 安定化組成物 - Google Patents
安定化組成物 Download PDFInfo
- Publication number
- WO2004037293A1 WO2004037293A1 PCT/JP2003/013419 JP0313419W WO2004037293A1 WO 2004037293 A1 WO2004037293 A1 WO 2004037293A1 JP 0313419 W JP0313419 W JP 0313419W WO 2004037293 A1 WO2004037293 A1 WO 2004037293A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aldehyde
- substance
- low
- molecular
- active substance
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 172
- 239000013543 active substance Substances 0.000 claims abstract description 186
- 239000000126 substance Substances 0.000 claims abstract description 158
- 239000003381 stabilizer Substances 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 150000001412 amines Chemical group 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 20
- 150000002337 glycosamines Chemical class 0.000 claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 7
- 150000003973 alkyl amines Chemical class 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims description 218
- 239000000843 powder Substances 0.000 claims description 73
- 239000008194 pharmaceutical composition Substances 0.000 claims description 68
- 229960003194 meglumine Drugs 0.000 claims description 31
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 28
- 230000001771 impaired effect Effects 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- 238000005469 granulation Methods 0.000 claims description 18
- 230000003179 granulation Effects 0.000 claims description 18
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 230000006641 stabilisation Effects 0.000 claims description 8
- 238000011105 stabilization Methods 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
- 235000014852 L-arginine Nutrition 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 6
- 239000010419 fine particle Substances 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 3
- 102000007327 Protamines Human genes 0.000 claims description 3
- 108010007568 Protamines Proteins 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- 229940048914 protamine Drugs 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical group 0.000 claims description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 2
- 239000004503 fine granule Substances 0.000 claims description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 15
- 108010009736 Protein Hydrolysates Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000003712 glycosamine group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 abstract description 75
- -1 aminosugar alcohols Chemical class 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 description 127
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 77
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 56
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 50
- 229940126062 Compound A Drugs 0.000 description 43
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 43
- 238000009472 formulation Methods 0.000 description 36
- 235000010355 mannitol Nutrition 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 29
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 29
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 29
- 235000019359 magnesium stearate Nutrition 0.000 description 28
- 239000008213 purified water Substances 0.000 description 27
- 229930195725 Mannitol Natural products 0.000 description 22
- 239000000594 mannitol Substances 0.000 description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 21
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 21
- 239000008108 microcrystalline cellulose Substances 0.000 description 21
- 229940016286 microcrystalline cellulose Drugs 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000654 additive Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 17
- 229920002678 cellulose Polymers 0.000 description 16
- 239000001913 cellulose Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 15
- 235000010980 cellulose Nutrition 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 229930006000 Sucrose Natural products 0.000 description 14
- 238000005507 spraying Methods 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 13
- 239000007884 disintegrant Substances 0.000 description 13
- 239000011521 glass Substances 0.000 description 13
- 239000008101 lactose Substances 0.000 description 13
- 239000005720 sucrose Substances 0.000 description 13
- 239000004698 Polyethylene Substances 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 229920000573 polyethylene Polymers 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 150000008064 anhydrides Chemical class 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 239000003518 caustics Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 125000003172 aldehyde group Chemical group 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 238000004898 kneading Methods 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 238000004080 punching Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 229960002920 sorbitol Drugs 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229920001903 high density polyethylene Polymers 0.000 description 6
- 239000004700 high-density polyethylene Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 5
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 239000007771 core particle Substances 0.000 description 5
- 239000008098 formaldehyde solution Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 235000010447 xylitol Nutrition 0.000 description 5
- 239000000811 xylitol Substances 0.000 description 5
- 229960002675 xylitol Drugs 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 239000004386 Erythritol Substances 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000019414 erythritol Nutrition 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- 229940009714 erythritol Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 4
- 238000010030 laminating Methods 0.000 description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 3
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101000642823 Solanum tuberosum Granule-bound starch synthase 2, chloroplastic/amyloplastic Proteins 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000009775 high-speed stirring Methods 0.000 description 3
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 description 3
- 229960005384 hydralazine hydrochloride Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- SGOQPVNCESJGKF-UHFFFAOYSA-N 2-hydrazinyl-2-(hydroxymethyl)propane-1,3-diol Chemical compound NNC(CO)(CO)CO SGOQPVNCESJGKF-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102000002419 Motilin Human genes 0.000 description 2
- 101800002372 Motilin Proteins 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005233 alkylalcohol group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- 235000012255 calcium oxide Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000007806 chemical reaction intermediate Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100013145 Drosophila melanogaster Flo2 gene Proteins 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 229920001007 Nylon 4 Polymers 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- MGJURKDLIJVDEO-UHFFFAOYSA-N formaldehyde;hydrate Chemical compound O.O=C MGJURKDLIJVDEO-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910001389 inorganic alkali salt Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 238000009517 secondary packaging Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical group C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Definitions
- the present invention relates to a composition
- a composition comprising a substance capable of supplying an aldehyde-like substance, comprising a low-molecular-weight active substance whose stability is impaired by the influence of an aldehyde, and a stabilizer having an amine structure and absorbing an aldehyde.
- the present invention relates to a composition to be blended (hereinafter, sometimes simply referred to as the composition of the present invention) and a method for stabilizing the low-molecular-weight active substance.
- compositions such as pharmaceuticals, cosmetics, and hair care products
- additives it is necessary to consider the reactivity with the low molecular weight active substance.
- Japanese National Publication of International Patent Application No. Hei 10-0-250-355 discloses N-acetyl-L
- conjugates having a primary or secondary amamine in the structure are liable to form an imine or enamine which is a reversible reaction intermediate with a compound having a formaldehyde or an aldehyde group.
- Orire, In (Stanley H. Pine) is liable to form an imine or enamine which is a reversible reaction intermediate with a compound having a formaldehyde or an aldehyde group.
- solid pharmaceutical compositions or the various additives forming them are known to contain, to a small extent, formaldehyde or other aldehyde-like substances. It is also known to produce formaldehyde or other aldehyde-like substances when excipients or solid pharmaceutical compositions are stored under hot and humid conditions [Pharmaceutical Research], 1998, Volume 15, Volume 7 Pp. 1026-1030, and Journal of Pharmaceutical Sciences, 1994, Vol. 83, No. 7, p. 915-921].
- JP-A-3-41033 discloses a freeze-dried motilin containing motilin and at least one stabilizing agent selected from saccharides, amino acids, inorganic salts and proteins acceptable in pharmaceutical compositions. Pharmaceutical compositions have been described. However, this publication is concerned with stabilization of a polymer substance in a freeze-dried pharmaceutical composition, but does not describe the effect of aldehyde at all.
- An object of the present invention is to provide an aldehyde-like substance in the fields of pharmaceuticals, cosmetics, hair treatment products, and the like in a composition containing a supplyable substance, and to stabilize an aldehyde of a low-molecular-weight active substance whose stability is impaired by the influence of the aldehyde. It is to provide a composition in which the above is improved.
- an aldehyde-like substance-suppliable substance incorporated in the composition for example, an aldehyde group-containing excipient
- the active substance is modified during the preparation process or storage of the composition by a substance such as an agent, which has the disadvantage of reducing the activity, and various studies have been conducted on methods for preventing such a decrease in activity.
- a compound having an amine structure capable of absorbing aldehyde should be blended as a stabilizer.
- the present inventors have found that such a decrease in the activity of the active substance can be effectively suppressed, and completed the present invention.
- the present invention provides the following various compositions and stabilization methods.
- Composition containing an aldehyde-like substance-suppliable substance, comprising a low-molecular-weight active substance whose stability is impaired by the influence of an aldehyde, and a stabilizer having an amine structure and absorbing aldehyde.
- the stabilizing agent is chitin, chitosan, chitooligosaccharide, megmin, alanine, anoreginin, lysine, hydroxylysine, gelatin or a hydrolyzate thereof, collagen or a hydrolyzate thereof, a / lebumin or a hydrolysis thereof.
- composition according to the above [1] which is produced by uniformly mixing a low-molecular-weight active substance and a stabilizer.
- composition according to the above-mentioned [11] which is a tablet obtained by tableting granules and Z or fine granules containing a low-molecular-weight active substance and granules and XI / or fine granules containing a stabilizer. .
- FIG. 1 is a schematic view of a glass test tube with a stopper for checking aldehyde generation.
- Figure 2 is a schematic view of a glass test tube with a stopper for confirming the reaction between a low-molecular-weight active substance and an aldehyde.
- FIG. 3 is a schematic view of a glass test tube with a stopper for confirming the reaction between a low-molecular-weight active substance and an aldehyde in a pharmaceutical composition.
- Figure 4 is a schematic diagram of a glass test tube with a stopper for confirming the aldehyde absorption effect of the stabilizer.
- composition of the present invention is based on the effects of aldehyde-like substance-suppliable substances and aldehydes.
- composition of the present invention may be any composition such as pharmaceuticals, cosmetics, and hair treatment products.
- an “aldehyde-like substance-suppliable substance” is a substance capable of supplying an “aldehyde that impairs the stability of a low-molecular-weight active substance” described below, and has an aldehyde structure itself. It may be a substance or a substance capable of producing or generating a compound having an aldehyde structure during preparation or storage of the composition.
- the “substance capable of supplying an aldehyde-like substance” may be a substance capable of generating or generating a compound having an aldehyde structure itself, or may be other components or other components in the composition.
- the substance may be capable of forming or generating a compound having an aldehyde structure as a result of interaction with environmental factors (eg, moisture, oxygen, carbon dioxide).
- environmental factors eg, moisture, oxygen, carbon dioxide.
- Specific examples of the “substance capable of supplying an aldehyde-like substance” include, for example, compounds having an aldehyde structure (for example, formaldehyde, acetoaldehyde, propionaldehyde, n-butyl aldehyde, isobutyl aldehyde, n-Barrel aldehyde, isovaleraldehyde), a carbohydrate that itself has an aldehyde structure in the structure (glucose, galactose, mannose, xylose, etc.), has an aldehyde group in the structure by hydrolysis in the composition
- Additives that become carbohydrates for example, oligosaccharides such as lactose, sucrose, and treha
- a low-molecular-weight active substance whose stability is impaired by the influence of an aldehyde (hereinafter sometimes simply referred to as a low-molecular-weight active substance) is used in the composition of the present invention.
- Any compound may be used as long as it is a low-molecular substance having some useful effect, for example, a pharmacological activity and generates an analogous substance by reacting with an aldehyde.
- a low-molecular-weight active substance is a substance that generates an analogous substance by reacting with an aldehyde can be confirmed, for example, by the method of Experimental Example 2 described below.
- low-molecular-weight active substances include compounds having a primary amine structure or a secondary amine structure.
- a compound having a hydrazine structure or a tryptamine structure is also included.
- Specific examples of the low-molecular-weight active substance in the case of a pharmaceutical composition include dopamine, methyldopa, norepinephrine, pakuguchifen, hydralazine, epinephrine, isoproterenore, nadrol, allobuterinol, ephedrine, hue-refrin, and echirefrin. , Propranolol, [3—
- aldehyde that impairs the stability of a low-molecular-weight active substance means a compound having an aldehyde structure, and includes, for example, formaldehyde, acetoaldehyde, propionaldehyde, n-butylyl, isobutyraldehyde, and n-butylaldehyde.
- Examples include valeraldehyde and isovaleraldehyde.
- Carbohydrates which themselves have an aldehyde group in the structure, that is, aldoses such as glucose, galactose, mannose and xylose are also included.
- the supply of these aldehydes in the composition is carried out when the above-mentioned compound having an aldehyde structure itself is present in the composition, and the substance which produces or generates the compound having an aldehyde structure in the composition is contained in the composition. It may be any of the cases in which That is, “aldehydes that impair the stability of low molecular weight actives” are produced or generated as a result of interactions with other components or environmental factors (eg, moisture, oxygen, carbon dioxide) in the composition. It may be something.
- Additives that generate or generate compounds having an aldehyde structure in the composition include oligosaccharides such as lactose, sucrose, trehalose, etc., which become saccharides having an aldehyde group in the structure by hydrolysis, starch, and cellulose. And the like. Also included are sugar alcohols such as mannitol, sorbitol, xylitol and erythritol, which become saccharides having an aldehyde group in the structure by the oxidation reaction.
- oligosaccharides such as lactose, sucrose, trehalose, etc.
- sugar alcohols such as mannitol, sorbitol, xylitol and erythritol, which become saccharides having an aldehyde group in the structure by the oxidation reaction.
- lower alkyl alcohols such as alcohol and ethyl alcohol, polyethylene alcohol or its fatty acid ester, polyethylene dalicol or its fatty acid ester are additives that generate or generate a compound having an aldehyde group in the composition.
- the “stabilizer having an amine structure and absorbing an aldehyde” (hereinafter, may be simply referred to as a stabilizer) used in the present invention includes: (1) a stabilizer having an amine structure; 2) A stabilizer capable of absorbing aldehyde and having the two characteristics of simultaneously. Whether or not the stabilizer absorbs aldehyde can be confirmed, for example, by the method of Experimental Example 4 described later.
- the stabilizing agent those having safety acceptable in the field of each composition are used.
- Specific examples include an amino sugar or a polymer thereof, an amino sugar alcohol or a polymer thereof, an amino acid or a polymer thereof, a protein or a hydrolyzate thereof, an alkylamine, a hydroxyanoleylamine, and a salt thereof. .
- These stabilizers may be used alone or in combination of two or more.
- amino sugar examples include N-acetylgalactosamine, N-acetinole darcosamine, galactosamine, and gnorecosamine.
- a salt of an amino sugar, a polymer of an amino sugar or a salt thereof can also be used.
- polymer of an amino sugar examples include chitin, chitosan, and chitooligosaccharide.
- amino sugar alcohol means a sugar alcohol having an amino group, and includes, for example, meglumine.
- a salt of an amino sugar alcohol, a polymer of an amino sugar alcohol or a salt thereof can also be used.
- amino acid includes, for example, basic amino acids, and more specifically, alanine, anoreginin, lysine, hydroxythyridine, and ordinine. Also,
- amino acids also include glutamine, asparagine, citrulline and the like.
- Amino acid salts, amino acid polymers or salts thereof can also be used.
- Examples of the “polymer of amino acid” include polylysine.
- Proteins include, for example, gelatin, collagen, albumin, casein, and protamine. Protein salts can also be used. In addition, a protein hydrolyzate can also be used.
- alkylamine includes a straight-chain or branched-chain alkynolamine having 1 to 6 carbon atoms, such as getylamine, hexylamine, or a salt thereof.
- Hydroalkylamine includes a group in which one to three hydroxy groups have been substituted for the above-described alkylamine, and examples thereof include tris (hydroxymethyl) aminomethane or a salt thereof.
- an anion exchange resin having an amino group as a functional group eg, cholestyramine (trade name: Amberlite IRP43), DEAE-cellulose, DEAE-agarose, meglumine-cellulose) and the like are also used.
- Preferred stabilizers for use in the present invention include meglumine, tris (hydroxymethyl) aminoaminomethane, L-arginine, gelatin, or salts thereof.
- salt means an acid addition salt, an alkali metal salt, an alkaline earth metal salt or a salt with an organic base.
- the acid addition salts include, for example, inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, and phosphate, oxalate, maleate, and fumaric acid Organic salts such as salt, malonate, lactate, malate, citrate, tartrate, benzoate, methane snolenate, p-toluenesulfonate, dalconate and the like.
- alkali metal salt examples include inorganic alkali salts such as sodium salt and potassium salt
- examples of the alkaline earth metal salt include calcium salt and magnesium salt
- examples of the salt with an organic base include: Examples thereof include salts with ammoea, methylamine, triethylamine, tributylamine, disopropylethylamine, N-methylmorpholine, and dihexylhexylamine.
- the stabilizer used in the composition of the present invention includes the weight of the aldehyde-like substance-suppliable substance present in the composition and its reactivity, the amount of the aldehyde-like substance supplied in the composition, and the weight of the low-molecular-weight active substance. And its molecular weight and their reactivity with aldehydes, and the reactivity with aldehydes of the stabilizing agent, etc., but those with higher reactivity based on the reactivity of low-molecular-weight active substances with aldehydes Is preferably selected as a stabilizer.
- the amount of the stabilizer used in the composition of the present invention depends on the amount of alcohol present in the composition. Weight of aldehyde-like substance supplyable substance, amount of aldehyde supplied in composition, reactivity of aldehyde with low molecular weight active substance, weight of low molecular weight active substance and its molecular weight, total weight of composition, other properties Considering the above, select as appropriate.
- the composition of the present invention is produced by uniformly mixing a low molecular weight active substance and a stabilizer with a substance capable of supplying an aldehyde-like substance. That is, the low-molecular-weight active substance and the stabilizer are added to the aldehyde-like substance-suppliable substance simultaneously or sequentially, and if necessary, other additives are added, followed by mixing or kneading by a conventional method to obtain a homogeneous composition. I do.
- the composition of the present invention comprises pre-granulating either the low molecular weight active substance or the stabilizing agent together with the aldehyde-like substance-suppliable substance, and then uniformly homogenizing the other. It can be manufactured by mixing.
- the stabilizing agent is pre-granulated together with the aldehyde-like substance-suppliable substance, and then uniformly mixed with the low molecular weight active substance. According to this method, the contact between the aldehyde-like substance-suppliable substance and the low-molecular active substance is prevented or reduced, so that a composition in which the low-molecular active substance is more stably retained can be obtained.
- a composition of the present invention comprises separately preparing an aggregate containing a low molecular weight active substance and an aggregate containing a stabilizer, wherein the aldehyde-like substance is supplied.
- the possible substance is contained in one or both of the two aggregates, and then the two aggregates are combined and mixed or kneaded.
- the term “aggregate” refers to a substance containing a low-molecular-weight active substance or a stabilizing agent, optionally containing an aldehyde-like substance-suppliable substance, and Z or other additives. This means that even after the composition is formed, the low-molecular-weight active substance or the stabilizing agent respectively constitutes a region which remains contained at a relatively high concentration. More specifically, “aggregate” refers to a granule obtained by mixing or kneading a low-molecular-weight active substance or a stabilizing agent, if necessary, together with a substance capable of supplying an aldehyde-like substance and / or other additives. Or means fine granules.
- the granules and fine granules are not particularly limited as long as they are granulated materials (the granulation method may be either dry or wet).
- the granulation method may be either dry or wet.
- granules and fine granules according to the pharmaceutical composition of the present invention are However, it preferably has a particle size specified in the Japanese Pharmacopoeia 14th Edition.
- granules are When conducting a particle size test of the agent, the entire amount passed through the No. 10 (1700 ⁇ ) sieve, and the amount remaining in the No. 12 (1400 ⁇ ) sieve was 5% or less of the total amount.
- it means a drug product that passes 15% or less of the total amount through a No. 42 (355 ⁇ 5 ⁇ ) sieve.
- fine granules are defined as "When conducting a particle size test of a drug product, those that pass through all of the No. 18 (850 / im) sieve and remain on the No. 30 (500 / m) sieve Not more than 5% of the total amount, and less than 10% of the total amount passes through a No. 200 (75 m) sieve. "
- the particle size of the granules or fine particles is, for example, from 1 tm to 5 mm, preferably from 10 ⁇ to 1 ⁇ , and more preferably from 20 ⁇ m to 500 ⁇ .
- the “aggregate” may be granules or fine granules themselves, or may be granules or fine granules that have been physically destroyed in a formulation step of producing a pharmaceutical composition.
- the “aggregate” may be granules or fine particles that retain the original shape, for example, contained in capsules or the like, or may be physically crushed in the tableting process or the like to recover the original shape. May not be retained, but may be a region containing a low-molecular-weight active substance or a stabilizer at a high concentration. Further, the “aggregate” may be a nucleus constituting a nucleated granule, or an area attached to the nucleated granule (including partial and total covering).
- compositions of the present invention include those used for various uses such as pharmaceuticals, cosmetics, and hair treatment products, and the most important composition is a pharmaceutical composition.
- the pharmaceutical composition of the present invention is a composition containing a low-molecular-weight active substance, which is always a solid powder, and a stabilizer, and is preferably a solid or semi-solid pharmaceutical composition.
- a low-molecular-weight active substance which is always a solid powder, and a stabilizer
- Specific examples include powders, fine granules, granules, tablets, capsules, powder injections, powder inhalants, ointments and patches.
- the above capsules include hard capsules or soft capsules filled with powders, fine granules, granules, tablets, and ointments.
- Granules and fine granules mean, for example, granules and fine granules having a particle size prescribed in the Japanese Pharmacopoeia, 14th Edition
- the pharmaceutical composition in which at least one of these aggregates is mixed with a substance capable of supplying an aldehyde-like substance is preferably a solid pharmaceutical composition, and specific examples include granules, fine granules, tablets, and capsules. Particularly preferred are tablets and capsenoles.
- the tablet includes an orally disintegrating tablet, a tuapur tablet, a sublingual tablet and the like.
- the pharmaceutical composition may be a dissolution-type preparation for use.
- the low-molecular-weight active substance and the stabilizer used in the preparation of the pharmaceutical composition of the present invention are solid (crystalline, non-crystalline) powders, and can be used as they are. It may be pulverized by using an energy mill, a hammer mill, a ball mill, a vibrating ball mill, a planetary ball mill, or the like, and then pulverized so that the average particle diameter becomes 200 ⁇ m or less. It is preferably used as fine particles of 100 / zm or less, more preferably 50 / m or less. Further, the crystallization conditions may be appropriately adjusted in the final step of the synthesis, or the particle diameter may be appropriately adjusted using a supercritical fluid technique without using a pulverization step.
- the stabilizer used in the pharmaceutical composition of the present invention it is preferable to select a stabilizer having higher reactivity based on the reactivity of the low-molecular-weight active substance with aldehyde.
- the amount of the stabilizer added depends on the reactivity of the aldehyde with the low molecular weight active substance, the molecular weight of the low molecular weight active substance, and other properties. It is added in a ratio of 0.001 to 100 parts by weight to 1 part by weight of the substance. Preferably, 0.01 to 100 parts by weight is added to 1 part by weight of the low molecular weight active substance. More preferably, 0.1 to 50 parts by weight is added to 1 part by weight of the low molecular weight active substance. Most preferably, 0.2 to 20 parts by weight is added to 1 part by weight of the low molecular weight active substance.
- the blending ratio of the low-molecular-weight active substance-containing aggregate and the stabilizer-containing aggregate is 0.1: 1 to 100 to 100: 0.01 (weight ratio, the same applies hereinafter), preferably 0.1 : 50 to 50: 0.1, more preferably 0.1: 10 to 10: 0.1.
- the amount of the stabilizer added should be determined based on the total weight of the aldehyde-like substance-suppliable substance in the pharmaceutical composition. is there.
- the stabilizer is used in an amount of 0.001 to 0.5 parts by weight, preferably 0.001 to 0.1 parts by weight, based on the total weight of the aldehyde-like substance-suppliable substance. More preferably, the calorie is added at a ratio of 0.05 to 0.05 parts by weight.
- the stabilizer is usually used in an amount of 0.001 to 0.5 parts by weight based on the total weight of the pharmaceutical composition. Parts. Preferably, it is added in a ratio of 0.001 to 0.1 part by weight based on the total weight of the pharmaceutical composition. More preferably, it is added in a ratio of 0.005 parts by weight to 0.05 parts by weight based on the total weight of the pharmaceutical composition.
- the amount of the stabilizer in the pharmaceutical composition of the present invention is based on the weight of the low-molecular-weight active substance in the pharmaceutical composition or based on the weight of the aldehyde-like substance-suppliable substance in the pharmaceutical composition. Or the force determined based on the total weight of the pharmaceutical composition. In any case, it is desirable to select and use an amount that can stabilize the low molecular weight active substance in the pharmaceutical composition most.
- a low-molecular-weight active substance and a stabilizer can be uniformly mixed with an aldehyde-like substance-suppliable substance.
- a predetermined amount of a low-molecular-weight active substance and a stabilizing agent are simultaneously or sequentially added to a pharmaceutical carrier containing an aldehyde-like substance-suppliable substance in a mixer, and if necessary, other additives are added and mixed uniformly.
- a pharmaceutical carrier containing an aldehyde-like substance-suppliable substance in a mixer, and if necessary, other additives are added and mixed uniformly.
- wetting agents, binders, disintegrants, etc. are added in the usual way and commercialized through processes such as kneading, granulating, drying, sizing and sieving. Is done.
- it can be produced by pre-granulating one of the low molecular weight active substance and the stabilizer together with the aldehyde-like substance-suppliable substance, and then uniformly mixing the other. it can. More preferably, after pre-granulating the stabilizer with the aldehyde-like substance-suppliable substance and then uniformly mixing with the low-molecular-weight active substance, the contact between the aldehyde-like substance-suppliable substance and the low-molecular-weight active substance can be prevented or prevented. Can be manufactured to be reduced.
- a method in which a low-molecular-weight active substance is granulated in advance with a substance capable of supplying an aldehyde-like substance and then uniformly mixed with a stabilizer will be referred to as a post-stabilizer addition method.
- a method for producing by preliminarily granulating with a substance capable of supplying an aldehyde-like substance and then uniformly mixing it with a low-molecular-weight active substance may be referred to as a low-molecular-weight active substance post-addition method.
- the pharmaceutical composition of the present invention is a granule, a tablet or a capsule
- either the stabilizer or the low-molecular-weight active substance is preliminarily granulated (core particles) together with the aldehyde-like substance-suppliable substance.
- the other can be added as a component of a coating such as sugar coating, film coat or capsule.
- an aggregate containing a low-molecular-weight active substance and an aggregate containing a stabilizing agent are separately prepared, wherein the aldehyde-like substance-suppliable substance is added to one of the two aggregates.
- a pharmaceutical composition can be produced by containing both of them and then formulating a preparation using both aggregates.
- the low-molecular-weight active substance and the stabilizer are separately granulated in advance, and at this time, a substance capable of supplying an aldehyde-like substance is contained in one or both of the two granules, and then the both granules are mixed or kneaded.
- a pharmaceutical composition can be manufactured.
- the granules containing the low-molecular-weight active substance or the stabilizer are, for example, non-barrel (trade name; containing 75% (W / W) of sucrose and 25% (W / W) of corn starch).
- It may be a nucleated granule obtained by adhering (including partial and total coating) a low-molecular-weight active substance or a stabilizing agent to a spherical nucleus, respectively.
- a method for producing a pharmaceutical composition after previously forming the low-molecular-weight active substance and the stabilizer separately into granules or fine particles in advance may be described as a two-group granulation method.
- the aldehyde-like substance-suppliable substance may be either an aggregate (preferably granules) containing a low-molecular-weight active substance or an aggregate (preferably granules) containing a stabilizer, or a granule containing a stabilizer. It is preferable to include it only in the compound.
- the granules containing the low-molecular-weight active substance and the stabilizer-containing granules thus produced may be filled as they are into capsules to form capsules, and the mixture of these granules is tabletted by a conventional method to give tablets. You can also.
- these low molecular active substances The granules containing the stabilizer and the granules containing the stabilizer may be uniformly dispersed in the preparation, or may be present separately in each part of the preparation such as a multilayer tablet or a dry coated tablet.
- low molecular weight active substances or stabilizers are required for substantially spherical nuclei such as nonpareils (trade name; containing 75% (WZW) sucrose and 25% (W / W) corn starch), respectively.
- the pharmaceutical composition can also be produced by successively attaching (including partial and total coating) or laminating with the aldehyde-like substance-suppliable substance depending on the conditions. In addition, by attaching (including partial and total coating) or laminating the core with either the low molecular weight active substance or the stabilizing agent, and the other with an aldehyde-like substance-suppliable substance as necessary. Can also produce a pharmaceutical composition.
- the low-molecular-weight active substance and the nucleated granules containing the stabilizer produced in this manner may be filled as they are into capsenolle as they are, and the nucleated granules may be tableted by a conventional method to form tablets. You can also.
- the low-molecular-weight active substance is most stable by adopting the two-group granulation method among the various production methods described above.
- a modified pharmaceutical composition can be obtained. That is, in the pharmaceutical composition obtained by the two-part granulation method, the decrease in the activity of the low-molecular-weight active substance or the generation of related substances is suppressed as compared with the pharmaceutical compositions obtained by other various production methods.
- the thus-prepared pharmaceutical composition of the present invention can obtain good stability even when stored by any method such as heat seal packaging, PTP packaging, bottle filling, and the like.
- a highly moisture-proof secondary packaging such as aluminum pyro-coated is used, and in the case of bottle filling, high-density polyethylene bottles, glass bottles, etc. are used to provide better stability.
- Property is obtained.
- the best stability can be obtained by enclosing silica gel in a highly moisture-proof secondary package or bottle.
- One or more selected from a desiccant, a deoxidizer, a carbon dioxide gas absorbent, a water conditioner, and the like may be enclosed in the canister if necessary, if necessary.
- desiccants include silica gel, quicklime, processed calcium chloride, and silica.
- Alumina gel synthetic zeolite, diatomaceous earth, etc .
- oxygen scavengers metal powders such as iron powder (including metal halides as oxidation catalysts), sulfites, bisulfites, dithionites, hydroquinone, Catechol, resorcinol, pyrogallol, gallic acid, Rongalit, asconolevic acid, ascorbate, isoasconolevic acid, isoascorbate, sorbose, glucose, lignin, etc .; carbon dioxide absorbents include calcium hydroxide , Magnesium hydroxide, calcium oxide, magnesium oxide, soda lime, balalame, calcium silicate hydrate, etc .; as humidity regulators, polyethylene glycol, propylene glycol, inorganic salts, B-type silica gel, paper, cellulose Impregnated with saturated
- composition of the present invention will be described in more detail for each dosage form.
- the low-molecular-weight active substance and the stabilizing agent are uniformly mixed to form a formulation (an embodiment in which one is granulated in advance and then uniformly mixed with the other to form a formulation) ), And separately preparing the low-molecular-weight active substance-containing aggregate and the stabilizer-containing aggregate, and then formulating the formulation using both aggregates.
- the pharmaceutical composition of the present invention is a powder, a low-molecular-weight active substance and a stabilizing agent in which aggregates have been crushed in advance using an oscillator, a pin mill, a hammer mill, or the like, and a powder having an acceptable physical and chemical stability.
- Excipients lactose, mannitol, sorbitol, xylitol, trehalose, sucrose, erythritol, starch, crystalline cellulose, etc.
- V-type mixer double-cone type mixer
- ribbon Mix using a mold mixer, etc.
- Lubricants such as sugar fatty acid esters are further added to make uniform powder.
- a low-molecular-weight active substance and a stabilizing agent may be used in terms of physical and chemical stability.
- Excipients lactose, mannitol, sorbitol, xylitol, trehalose, sucrose, erythritol, starch, crystalline cellulose
- binders hydroxypropylcellulose, hydroxypropynolemethylcellulose, pullulan, polyviel
- disintegrants low-substituted hydroxypropylcellulose, carmellose calcium, croscarmellose sodium, cross-linked polypyrrolidone, lipoxymethyl starch sodium, etc.
- a kneading granulator high-speed stirring granulator or fluidized-bed granulator and dry the above low-molecular-weight active substance.
- the mixture of the stabilizing agent and the excipients may be added to calories, granulated, dried and sized to give granules. These granules can be used as granules as they are.
- tanolek for the purpose of preventing static electricity or improving fluidity, tanolek, light anhydrous calcium acid, magnesium aluminate metasilicate, stearic acid or salts thereof, sucrose fatty acid ester Or the like may be added to the outside as an adhesion inhibitor.
- the stabilizer of the present invention may not be added to fine granules or granules (hereinafter simply referred to as condyles), but may be added to the outside together with an antiadhesive agent.
- the pharmaceutical composition of the present invention is a tablet or a capsule
- a low-molecular-weight active substance usually 0.01 to: L 0 w / w% of the total weight of the pharmaceutical composition
- the stabilizer of the present invention To the granules containing the above, if necessary, externally added substances (excipients, disintegrants, lubricants, etc.) are added and mixed at an appropriate ratio to obtain a finished powder.
- This preparation is used for gelatin, It can be filled into a capsule made of droxypyrmethylcellulose or pullulan to form a capsule. Alternatively, tablets can be prepared by compression molding the prepared powder.
- the stabilizer of the present invention does not necessarily need to be added to the granules, but may be added to the outside of the granules containing the low molecular weight active substance. Or, conversely, for a granule containing a stabilizer (does not contain a low-molecular active substance), a low-molecular active substance and appropriate additive substances (excipients, disintegrants, lubricants, etc.) are externally added. Addition-mixing The prepared powder is filled into capsules to form capsules, and tablets may be made by compression molding.
- granules or tablets containing the above-mentioned low-molecular-weight active substance and stabilizing agent, to which no disintegrant is added are used as core particles or tablet cores.
- a controlled release granule or tablet can be produced by applying a control film and performing heat treatment (curing) as necessary.
- a drug dissolution controlling component consisting of a polymer, oil, or the like may be added to form a granule or tablet by the method described above, and heat treatment may be performed as necessary. Therefore, sustained release granules or tablets can be produced.
- the granules thus produced can be filled into a force capsule to form a force capsule.
- the pharmaceutical composition of the present invention is a powder injection, for example, aseptically produced powder of a low-molecular-weight active substance (including a lyophilized product) and a stabilization method of the present invention which is similarly sterilized Powders (including freeze-dried products) and, where necessary, additives commonly used in the preparation of such preparations, such as excipients (lactose, D-mannitol, D-sorbitol, pudose sugar, sucrose, etc.) ) Or pH regulators, osmotic pressure regulators, solubilizers, formulation stabilizers, etc. in appropriate proportions in ampoules, vials, or other suitable containers or kit containers.
- excipients lactose, D-mannitol, D-sorbitol, pudose sugar, sucrose, etc.
- pH regulators osmotic pressure regulators
- solubilizers solubilizers
- formulation stabilizers etc. in appropriate proportions in ampoules, vials, or other
- the pharmaceutical composition of the present invention is a powder inhalant
- a powder (including a lyophilized product) of a low-molecular-weight active substance which is prepared to have an appropriate particle size as an inhalant and is aseptically produced.
- the powder of the stabilizer of the present invention (including a lyophilized product), which has been sterilized, and if necessary, additives usually used in the preparation thereof, such as excipients (lactose, D-mannitol, D-sorbitol, dextrose, sucrose, etc.) or pH regulator, osmotic pressure regulator, solubilizer, formulation stabilizer, etc. at appropriate ratio into appropriate injection equipment for production.
- the pharmaceutical composition of the present invention is an ointment or a patch
- a powder of a low-molecular-weight active substance produced in an appropriate particle size as an external preparation and an appropriate particle size Apply the prepared powder of the stabilizer of the present invention to an ointment base or a patch at an appropriate ratio, if necessary, with a pH regulator, a preparation stabilizer, an absorption enhancer, etc., which are usually used in these preparations. It is dispersed in the base of the preparation using an appropriate device, and is manufactured by an ordinary method of an ointment or patch.
- the pharmaceutical composition of the present invention is in the form of fine granules or granules, for example, the low-molecular-weight active substance and the stabilizing agent are separately prepared by separately supplying the aldehyde-like substance-suppliable substance, physical and chemical substances.
- Stability-acceptable excipients eg, lactose, mannitol, sorbitol, xylitol, trehalose, sucrose, erythritol, starch, crystalline cellulose, sucrose, pudose, corn starch, kanzo powder, sodium bicarbonate, Calcium phosphate, calcium sulfate), binders (e.g., hydroxypropyl senorellose, hydroxypropinolemethinoresenorelose, punorelane, polyvinylinolepyrrolidone, gelatin, starch, gum arabic, tragacanth, carboxymethylcellulose, sodium alginate, Glycerin), required Disintegrants in accordance with (e.g., low location ⁇ hydroxypropionic Pinot receptacle Honoré loin, Kano Leme loin Kano Residencial ⁇ beam, the cross power Noremero Sunatoriumu, crosslinked polyvinylpyrrolidone, carboxymethyl starch
- the aldehyde-like substance-suppliable substance may be the same as or different from an excipient, a binder, a disintegrant, and the like that are acceptable in terms of physical and chemical stability.
- the mixture thus obtained is obtained by a dry method using a slug tablet machine, a compression roller, or the like, or a wet granulation method using a kneading granulator, a high-speed stirring granulator, a fluidized bed granulating dryer, or the like.
- the above binder may be dissolved in a solvent such as water in advance and used as a binding solution, or a low molecular active substance or a stabilizer may be added to the binding solution. .
- the mixture containing a low-molecular-weight active substance or a stabilizing agent in a substantially spherical core such as, for example, a non-pareil (trade name; containing 75% of white sugar (WZW) and 25% of corn starch (WZW)).
- a substantially spherical core such as, for example, a non-pareil (trade name; containing 75% of white sugar (WZW) and 25% of corn starch (WZW)).
- the granules (or fine granules containing the low-molecular-weight active substance) thus obtained and the granules (or fine granules) containing the stabilizer are uniformly mixed and used as granules (or fine granules).
- talc, light silicic anhydride, magnesium metasilicate, magnesium aluminate, stearic acid or its salts eg, magnesium salt, calcium salt
- sucrose fatty acid esters etc. It can be added to the outside of granules (or fine granules).
- a low-molecular-weight active substance or a stabilizing agent is added to a substantially spherical core such as a nonpareil (trade name; containing 75% (W / W) of sucrose and 25% (W / W) of corn starch).
- a substantially spherical core such as a nonpareil (trade name; containing 75% (W / W) of sucrose and 25% (W / W) of corn starch).
- the nucleated granules containing the low-molecular-weight active substance and the stabilizer can also be obtained by sequentially adhering (including partial and total coating) or laminating the above-mentioned mixture.
- any of the above mixtures containing a low molecular weight active substance or a stabilizing agent may be nucleated.
- the nucleated granules containing the low-molecular-weight active substance and the stabilizing agent can also be obtained by adhering (including partially or completely covering) or laminating the other.
- the pharmaceutical composition of the present invention is a tablet or a capsule
- the low-molecular-weight active substance described in the above (II) 1.1 (usually 0.01-1-1 O w / w of the total weight of the pharmaceutical composition). %) Addition of additives (excipients, disintegrants, lubricants, etc.) at an appropriate ratio to the granules containing the stabilizer and the granules containing the stabilizer, if necessary.
- This preparation can be filled into capsules made of gelatin, hydroxypyrmethylcellulose or pullulan to form capsules.
- tablets can be prepared by compression-molding the prepared powder.
- a tablet in which the low-molecular-weight active substance-containing granules and the stabilizer-containing granules are uniformly dispersed in the preparation can be obtained. it can.
- tablets such as multilayer tablets and dry coated tablets can be obtained by separately forming the low-molecular-weight active substance-containing granules and the stabilizer-containing granules in each part of the preparation and compression-molding them. Specifically, either one of the granules containing the low-molecular-weight active substance or the granules containing the stabilizer is tableted together with additives (eg, excipients, disintegrants, lubricants) as necessary.
- additives eg, excipients, disintegrants, lubricants
- tablets obtained after tableting either the low-molecular-weight active substance-containing granules or the stabilizer-containing granules with additional substances (eg, excipients, disintegrants, lubricants) as necessary Is pressed as an inner core tablet and the other is coated as a coating component, whereby a dry coated tablet can be obtained.
- additional substances eg, excipients, disintegrants, lubricants
- tablets can be obtained in the same manner as described above using nucleated granules containing a low molecular weight active substance and a stabilizer.
- the fine granules, granules, tablets and capsules obtained in (II) -1. And (II) -12 above are coating agents for taste masking, easy solubility or sustained release, etc. May be coated.
- the coating agent examples include hydroxypropyl methylcellulose, ethinoresenorelose, hydroxymethinoresenorelose, and hydroxypropinoresenorelose.
- a light-shielding agent such as titanium oxide or red iron oxide may be used for the purpose of improving the photostability of the low-molecular-weight active substance.
- granules or tablets obtained by mixing the above-mentioned low-molecular-weight active substance-containing granules and stabilizer-containing granules, tablets or granules or tablets obtained by shaping into tablets of an appropriate size by crushing or the like The core particles or tablet cores without added disintegrants are used as core particles or tablet cores, coated with a drug elution control film composed of high molecular weights, oils and fats, and subjected to heat treatment (curing) as necessary. Controlled release granules or tablets can be prepared.
- a drug or a drug-eluting control component composed of oils and fats may be added to form granules or tablets by the above-mentioned method, and then subjected to a heat treatment if necessary. Sustained-release granules or tablets can be prepared. The granules thus produced can be filled into capsules to form capsules.
- the compound A described below is an example of the low-molecular-weight active substance of the present invention. [3 -— (2R) — [[(2R) — (3-chlorophenyl) -1-— Hydroxitytyl] amino] propyl] -1H-indole-17-yloxy] acetic acid.
- the sample is reacted with 0.1 mL of 0.1% 2,4-dinitrophenylhydrazine (DNP) in 4N aqueous hydrochloric acid to form a DNP derivative, and then mixed with 4N sodium hydroxide. After the addition, 20 ⁇ L was injected into a high-performance liquid chromatograph under the following conditions and measured.
- DNP 2,4-dinitrophenylhydrazine
- UV-visible absorption photometer detection wavelength: 345 nm
- Experimental Example 1--1 Experimental Example 1--2 Lactose (substance capable of supplying aldehyde-like substances) 71.0 parts-parts
- Compound A powder 2 mg was stored in a sealed glass test tube with a stopper filled with an aqueous formaldehyde solution (1 mL) prepared at each concentration (see Fig. 2), and added at 50 ° C for 14 days. The amount of the compound A analogous substance produced when heated was measured. The amount of related substances produced was determined by dissolving Compound A powder (2 mg) in 20 OmL of methanol to prepare a sample solution, and using a 10 ⁇ L solution of this solution and a high-speed liquid chromatograph under the following conditions. The peak area percentage of the related substance with respect to the total peak area value including the compound A was defined as the production amount.
- UV-visible absorption photometer detection wavelength: 220 nm
- Experimental example 3-1 Experimental example 3-2 Compound A (low molecular active substance) 0.1 part 0.1 part Lactose (substance capable of supplying aldehyde-like substance) 70.9
- D-mannitol (substance capable of supplying an aldehyde-like substance)-70.9
- Low-substituted hydroxypropylcellulose 10.0 10.0
- Hydroxypropinoresenololose 2.5
- Microcrystalline cellulose 15.0
- Magnesium stearate 1.0
- Light caustic anhydride 0.5 0.5 Total 100.0 parts 100.0 parts Table 5. Relationship between the amount of formaldehyde collected and the amount of related substances generated
- Amount of aldehyde produced Amount of aldehyde produced Amount collected (/ z g) (%) Amount collected (g) (%) At the start 0.14 0.22 2
- Example 1 The formulation components shown in Example 1, Example 2, and Comparative Example 1 in Table 7 were weighed according to the respective composition ratios and mixed in a magnetic mortar to obtain a powder containing Compound A.
- Example 1 The powders of Example 1, Example 2 and Comparative Example 1 were loaded into the bottom of a glass test tube with a stopper shown in Fig. 3 and sealed at 60 ° C in a sealed state (100% relative humidity). was stored for one week, and the amount of related substances produced was measured using a high-performance liquid chromatograph in the same manner as in Experimental Example 3. Table 8 shows the results.
- Comparative Example 2 in Table 9 The formulation components shown in Comparative Example 2 in Table 9 were weighed according to the respective composition ratios, and Compound A, lactose, or a low-substituted hydroxypropylcellulose were added to a fluidized bed granulated dry; »(FL ⁇ _2 type, Freund It was granulated by spraying an aqueous solution of hydroxypropylcellulose (5 wZ w%) in industry, dried, and sized using a stainless sieve (20 mesh) to obtain granules containing a low molecular active substance.
- Crystalline cellulose, magnesium stearate and light caustic anhydride were added to the low-molecular-weight active substance-containing granules and mixed using a polyethylene bag to give granules for tableting.
- the granules for tableting are compression-molded using a rotary set tableting machine (HT-AP 18 SS-II type, Hatatetsu) to produce compound A tablets.
- the formulation components shown in Comparative Example 3 in Table 9 were weighed according to the respective composition ratios, and the same operation as above was performed to obtain a compound A tablet.
- Comparative Examples 2 and 3 were filled in a high-density polyethylene bottle, and sealed for one month at 40 ° C and 75% RH in a sealed, sealed (silica gel sealed) and opened state.
- the production amount was measured using a high-speed liquid chromatograph in the same manner as in Experimental Example 3. Table 10 shows the results.
- Comparative Example 2 lactose-based formulation
- Comparative Example 3 mannitol-based formulation
- Lactose (Aldehyde-like substance can be supplied) 70.9-Child
- Active D-Mannitol 10.9 (substance capable of supplying aldehyde-like substances)
- Example 3 The formulation components shown in Example 3 in Table 11 were weighed according to the respective composition ratios, and compound A, D-mannitol and low-substituted hydroxypropylcellulose were added to a hydrolyzed gelatin aqueous solution (10 W w ° / o). After kneading and granulating using a universal mixing stirrer (5 MD type, Shinagawa Kogyosho), dry at 50 for 16 hours, and size using a stainless sieve (20 mesh). The low molecular weight active substance-containing granules were obtained.
- a universal mixing stirrer 5 MD type, Shinagawa Kogyosho
- Crystalline cellulose, magnesium stearate and light caustic anhydride were added to the low-molecular-weight active substance-containing granules and mixed using a polyethylene bag to give granules for tableting.
- the granules for tableting were compression-molded using a single-shot tableting machine (Kikusui Seisakusho) to obtain compound A tablets.
- Example 4 The formulation components shown in Example 4 in Table 11 were weighed according to the respective composition ratios, and Compounds A, D-mannitol, low-substituted hydroxypropylcellulose, and light caffeic anhydride were added to a fluidized bed granulating dryer (FLO- Granulation and drying by spraying a hydroxypropylcellulose aqueous solution (5 w / w%) in which medalmine was dissolved in advance in Type 2 (Freund Corporation) using a stainless sieve (20 mesh). The resulting mixture was sized to obtain granules containing a low molecular weight active substance.
- the resulting mixture was sized to obtain granules containing a low molecular weight active substance.
- Microcrystalline cellulose, magnesium stearate, and light caffeic anhydride were added to the low-molecular-weight active substance-containing granules, and mixed using a polyethylene bag to obtain granules for tableting.
- the granules for tableting were compression-molded using a rotary type tablet machine (HT-AP18SS-II type, Hatatsutesho) to obtain compound A tablets.
- Example 3 The tablets of Examples 3 and 4 were filled in a high-density polyethylene bottle, and stored for one month under the conditions of 40 ° C and 75% RH in a sealed stopper, stoppered (sealed with gel), and opened. Measured the amount of substance produced using a high-speed liquid chromatograph in the same manner as in Experimental Example 3. did. Table 12 shows the results.
- the amount of the analogous substances produced from the tablets of Examples 3 and 4 in which gelatin or meglumine was added as a stabilizer in the drug product was compared with the results of the tablets of Comparative Example 3 of the same mannitol monol-type formulation. It was clearly suppressed even under the preservation condition. In particular, when silica gel was encapsulated together with the tablet, the effect of suppressing the generation of related substances was even better.
- Example 3 Compound A (low molecular weight active substance) 0.1 part 0.1 part
- Microcrystalline cellulose, magnesium stearate, and light anhydrous silicic acid were added to the low-molecular-weight active substance-containing granules and mixed using a polyethylene bag to give granules for tableting.
- the granules for tableting were compression-molded using a rotary type tablet machine (HT-AP18SS-II type, Hatatsutesho) to obtain compound A tablets.
- Example 5 The tablets of Examples 5 and 6 were filled in a high-density polyethylene bottle, and stored for one month under the conditions of 40 ° C and 75% RH in a sealed stopper, sealed stopper (filled with silica gel) and opened.
- the amount of generated substances was measured using a high-speed liquid chromatograph in the same manner as in Experimental Example 3. The results are shown in Table 14.
- Example 7 Tablet manufactured by post-stabilizer addition method
- Example 7 The formulation components shown in Example 7 in Table 15 were weighed in accordance with the respective composition ratios, and Compounds A, D-mannitol, low-substituted hydroxypropylcellulose, and light caffeic anhydride were added to a fluidized bed granulating dryer (FLO- Hydroxypro in type 5 in Freund industry) It was granulated by spraying an aqueous pill cellulose solution (5%), dried, and sized using a stainless sieve (20 mesh) to obtain low molecular active substance-containing granules.
- FLO- Hydroxypro in type 5 in Freund industry
- Meglumine, microcrystalline cellulose, magnesium stearate, and light caffeic anhydride were added to the low-molecular-weight active substance-containing granules, and mixed using a polyethylene bag to obtain granules for tableting.
- the granules for tableting were compression-molded using a rotary tablet machine (HT-API 8 SS-II type, Hatatetsu) to obtain tablets of compound A after addition of meglumine.
- Example 7 The tablet of Example 7 was filled in a high-density polyethylene bottle, and stored for one month under the conditions of 40 ° C and 75% RH in a sealed (sealed gel) and opened state to produce analogous substances. The amount was measured using a high performance liquid chromatograph in the same manner as in Experimental Example 3. The results are shown in Table 16.
- the meglumine which is a stabilizer, is not in direct contact with the low-molecular-weight active substance, that is, the tablet of Example 7 is added together with the post-additive outside the low-molecular-weight active substance-containing granules, and the tablet is sealed.
- a sufficient stabilization effect of the low-molecular-weight active substance was obtained, and the granules containing the low-molecular-weight active substance were granulated with meglumine.
- Example 8 and Example 9 Tablets manufactured by the low molecular weight active substance post-addition method
- a mixture of A-drug A, D-mantol, crystalline cellulose, magnesium stearate and light anhydrous silicic acid were added and mixed using a polyethylene bag to give granules for tableting.
- the granules for tableting were compression-molded using a rotary type tablet machine (Clean Press Collect 19K type, Kikusui Seisakusho) to obtain a low-molecular-weight active compound 1 of compound A.
- Example 8 and 9 were filled in a high-density polyethylene bottle, and stored for one month under the conditions of 40 ° C and 75% RH in a sealed stopper, stoppered (sealed with gel), and opened.
- the amount of substance produced was measured using a high performance liquid chromatograph in the same manner as in Experimental Example 3. The results are shown in Table 18.
- Example 7 the meglumine and aldehyde-like substance capable of supplying a stabilizer were not brought into direct contact with the low-molecular-weight active substance, and the low-molecular-weight active substance was added to the outside of the meglumine granules together with the post-addition component.
- the stabilized tablets of Examples 8 and 9 have excellent stability under any of the storage conditions, and have superior stability to the tablets of Example 4 comprising granules containing a low-molecular-weight active substance granulated with medalmin. Was done. Furthermore, when silica gel is encapsulated together with the tablet, an extremely excellent effect of suppressing the production of related substances can be obtained.
- Example 10 of Table 19 The formulation components shown in Example 10 of Table 19 were weighed in accordance with the respective composition ratios, and hydralazine hydrochloride, lactose, low-substituted hydroxypropylcellulose, and meglumine were added to a fluidized bed granulating dryer (FLO-5B type). , In the Freund industry) The granules were dried by spraying an aqueous solution of lurose (5 w / w%) and sized using a stainless sieve (20 mesh) to obtain granules containing a low molecular active substance.
- FLO-5B type fluidized bed granulating dryer
- Crystalline cellulose, magnesium stearate and light silica anhydride were added to the low-molecular-weight active substance-containing granules, and mixed using a polyethylene bag to give granules for tableting.
- the granules for tableting were compression-molded using a rotary tablet machine (HT-API 8 SS-II, Hatatsutesho) to obtain stable hydralazine hydrochloride tablets.
- Example 11 of Table 19 The formulation components shown in Example 11 of Table 19 were weighed according to the respective composition ratios, and the same operation was performed as described above to obtain stable hydralazine hydrochloride tablets. Table 19
- Example 12 of Table 20 The formulation components shown in Example 12 of Table 20 were weighed in accordance with the respective composition ratios, and added to Bakuguchi Phen, D-mannitol, and low-substituted hydroxypropylcellulose.
- An aqueous solution of degraded gelatin (1 O w / w%) is added, and the mixture is kneaded and granulated using a universal mixing stirrer (5 MD type, Shinagawa Kogyosho), dried at 50 ° C for 16 hours, and subjected to a stainless steel sieve ( 20 mesh) to obtain granules containing a low-molecular-weight active substance.
- a universal mixing stirrer 5 MD type, Shinagawa Kogyosho
- microcrystalline cellulose, magnesium stearate, and light anhydrous silicic acid were added to the granules containing the low-molecular-weight active substance, and mixed using a polyethylene bag to obtain granules for tableting.
- the granules for tableting were compression-molded using a single-shot tableting machine (Kikusui Seisakusho) to obtain stable fluffy tablets.
- Example 13 of Table 20 The formulation components shown in Example 13 of Table 20 were weighed according to the respective composition ratios, and the same operation was performed as described above to obtain stable baclofen tablets. Table 20
- Example 14 of Table 21 The formulation components shown in Example 14 of Table 21 were weighed in accordance with the respective composition ratios, and D-mannitol and low-substituted hydroxypropylcellulose were subjected to fluidized bed granulation drying; (FLO-5 type ZB type Zl5, Freund Sangyo) is granulated by spraying a solution of medicamine dissolved in water (5%), and dried and dried with a stainless steel sieve (2). 0 mesh) to give meglumine granules.
- Ephedrine hydrochloride, D-mannitol, crystalline cellulose, magnesium stearate, and light caffeic anhydride were added to the medalmine granules, and mixed with a polyethylene bag to obtain granules for tableting.
- the granules for tableting were compression-molded using a rotary type tablet machine (Clean Press Collect 19K type, Kikusui Seisakusho) to obtain stable tablets of post-addition of a low molecular weight active substance of ephedrine hydrochloride.
- Example 15 of Table 21 The formulation components shown in Example 15 of Table 21 were weighed in accordance with the respective composition ratios, and the same operation as above was performed to obtain stable tablets of ephedrine hydrochloride.
- Example 16 Example 17 and Example 18:
- flow coater FLO-5B type
- Manthol and low-substituted hydroxypropinoresenorelose were placed in a flow coater (FLO-15 type), and granulated and dried with an aqueous solution of megnoremin and hydroxypropylcellulose to obtain stabilizer-containing granules. .
- the granules containing the low-molecular-weight active substance and the granules containing the stabilizer were each granulated using a granulator (twin rotor (with 32 mesh sieve)).
- a sized granule containing a low-molecular-weight active substance a sized granule containing a stabilizer, crystalline cellulose, magnesium stearate, and a light caustic anhydride mixer (V mixer (VM-10 type))
- V mixer VM-10 type
- the mixture was mixed for 0 minutes to obtain granules for tableting.
- the granules for tableting were converted into tablets using a rotary tableting machine (Clean Press, C19K).
- Binding Solution 1 62.5 g of hydroxypropylcellulose was dissolved in 1188 g of purified water to prepare Binding Solution 1.
- a fluidized bed granulated dry thigh FD-3S, Fuji Sangyo
- compound A 5.0 g, mannitol 1783 g and low-substituted hydroxypropylcellulose 25 O g are mixed uniformly and then combined in the machine Liquid 1 was sprayed and granulated, and then dried in a fluidized bed granulator to obtain granules of the active substance.
- hydroxypropyl cellulose and 50.0 g of meglumine were dissolved in 1188 g of purified water to prepare a binding solution 2.
- a fluidized bed granulator FD-3S, PAREC
- 25.0 g of light Ca-anhydride AERO SIL; Nippon AEROSIL
- 1713 g of Mannithonore 1713 g of Mannithonore
- 250 g of low-density hydroxypropylcellulose are mixed uniformly, and then on board.
- the solution was granulated by spraying the binding liquid 2 in, and then dried in a fluidized bed granulation dryer to obtain meglumine granules.
- the obtained two granules were pulverized using a power mill pulverizer (P-3, Showa Kagaku Kikai Seisakusho) with a 1.5 mm ⁇ punching screen to obtain sized powder.
- P-3 Showa Kagaku Kikai Seisakusho
- composition per tablet Prescription (composition per tablet):
- Binding Solution 1 Hydroxypropylcellulose (112.5 g) was dissolved in purified water (2138 g) to prepare Binding Solution 1.
- FD_5 S, PAREC fluidized bed granulator dry
- 9.0 g of compound A, 3209 g of mannitol, and 450 g of low-substituted hydroxypropylcellulose are mixed uniformly, and then granulated by spraying the binding liquid 1 in the machine. Then, it was dried in a fluidized-bed granulated dry thigh to obtain the active drug granules.
- Binding Solution 2 112.5 g of hydroxypropyl cellulose and 90.0 g of megnoremin were dissolved in 2138 g of purified water to prepare Binding Solution 2.
- a fluidized bed granulating dryer FD-5S, Parec
- the binder 2 is sprayed in the machine to granulate, Then, it was dried in a fluidized bed granulation dryer to obtain meglumine granules.
- the obtained two granules were crushed with a 1.5 mm ⁇ punching screen using a power mill crusher (P-3, Showa Chemical Machinery Works) to obtain sized powder.
- P-3 Showa Chemical Machinery Works
- 3486 g of the sized powder containing the active ingredient obtained 3486 g of the sized powder containing meglumine, 1245 g of microcrystalline cellulose and 83.0 g of magnesium stearate were added and mixed with a tumbler mixer (TM-60S, Showa Chemical Machinery Works). And granules for tableting.
- the resulting granules are tableted with a rotary tableting machine (Correct 12HUK, Kikusui Seisakusho) using a 6.5 mm ⁇ punch with a weight of 100 mg (tabletting pressure 6 KNZ punch), each containing 0.1 mg of Compound A per tablet.
- a tablet having the following formulation was obtained.
- Binding Solution 1 Hydroxypropyl cellulose (112.5 g) was dissolved in purified water (2138 g) to prepare Binding Solution 1. 18.0 g of Compound A, 3200 g of Mannithonole and 450 g of low-substituted hydroxypropylcellulose were uniformly mixed in a fluidized bed granulator (FD-5S, No. 1 was granulated by spraying, and then dried in a fluidized bed granulation drying machine to obtain a main drug granule.
- FD-5S fluidized bed granulator
- Binding Solution 2 112.5 g of hydroxypropylcellulose and 90.0 g of meglumine were dissolved in 2138 g of purified water to prepare Binding Solution 2.
- a fluidized-bed granulator / dryer FD-5S, Parec
- granulation is performed by spraying Binder 2 in the machine, followed by fluidization. It was dried in a layer granulation dryer to obtain meglumine granules.
- the obtained two granules were crushed with a 1.5 mm ⁇ punching screen using a power mill crusher (P-3, Showa Chemical Machinery Works) to obtain sized powder.
- P-3 Showa Chemical Machinery Works
- Example 22 112.5 g of hydroxypropylcellulose was dissolved in 2138 g of purified water to prepare Binding Solution 1. After uniformly mixing 27.0 g of compound A, 3191 g of mannitol and 450 g of low-substituted hydroxypropyl cellulose in a fluidized bed granulator (FD-5S, NO. 1 was sprayed and granulated, and then dried in a fluidized bed granulating dryer to obtain a main drug granule.
- FD-5S, NO. 1 fluidized bed granulator
- Binding Solution 2 112.5 g of hydroxypropyl cellulose and 90.0 g of meglumine were dissolved in 2138 g of purified water to prepare Binding Solution 2. After uniformly mixing 3128 g of manthol and 450 g of low-substituted hydroxypropylcellulose in a fluidized-bed granulator / dryer (FD-5S, Parec), granulation is performed by spraying the binding liquid 2 in the machine, and then flowing. It was dried in a layer granulator to obtain medalmine granules.
- FD-5S fluidized-bed granulator / dryer
- the obtained two granules were crushed with a 1.5 ⁇ punching screen using a power mill (P-3, Showa Chemical Machinery Works) to obtain sized powder.
- composition per tablet Prescription (composition per tablet):
- Binding Solution 2 12.5 g of hydroxypropylcellulose and 90.0 g of meglumine were dissolved in 2138 g of purified water to prepare Binding Solution 2.
- a fluidized bed granulating dryer FD-5S Parec
- the binder 2 is sprayed in the machine to granulate, and then the fluidized bed is granulated. It was dried in a granulation dryer to obtain medalmine granules.
- the obtained two granules were pulverized with a power mill mill (P_3, Showa Chemical Machinery Works) using a 1.5 ⁇ punching screen to obtain sized powder.
- P_3 Showa Chemical Machinery Works
- composition per tablet Prescription (composition per tablet):
- hydroxypropyl cellulose is dissolved in 1323 g of purified water to prepare a hydroxypropyl cellulose solution 2.
- 4.5 g of yellow iron sesquioxide was dispersed in 630 g of purified water using Lab Disper (Chuo Rika), and 90 g of meglumine, 90 g of purified water, and hydroxypropylcellulose solution 2 were mixed.
- a fluidized bed granulating dryer FD-5S, Bowrec
- the binder solution 2 is sprayed in the machine, and granulated. Drying was performed in a fluidized bed granulator to obtain medalmine granules.
- the two granules obtained were crushed with a 1.5 mm ⁇ punching screen using a Powermino crusher (P-3, Showa Chemical Machinery Works) to obtain sized powder.
- P-3 Showa Chemical Machinery Works
- the obtained granules were tableted with a rotary tableting machine (Correct 12HUK, Kikusui Seisakusho) using a punch with a long diameter of 8.5 mm and a short diameter of 5 mm at a weight of 10 Omg (tablet pressure 4 KN / punch), and 1 tablet A tablet having the following formulation containing 0.2 mg of Compound A per unit was obtained.
- a rotary tableting machine Correct 12HUK, Kikusui Seisakusho
- composition per tablet Prescription (composition per tablet):
- Hydroxypropylcellulose (11.25 g) is dissolved in purified water (1415 g) to prepare a hydroxypropylcellulose solution (1).
- 2.25 g of yellow iron sesquioxide was dispersed in 630 g of purified water using Lab Disper (Chuo Rika), and 90 g of purified water and a hydroxypropylcellulose solution 1 were mixed to obtain a binding solution 1.
- the binding solution 1 was mixed in the machine. It was granulated by spraying and then dried in a fluidized-bed granulator to obtain the active drug granules.
- hydroxypropyl cellulose is dissolved in 1325 g of purified water to prepare a hydroxypropyl cellulose solution 2.
- 2.25 g of yellow ferric oxide was dispersed in 630 g of purified water using Lab Disper (Chuo Rika), and 90.0 g of meglumine, 90.0 g of purified water, and hydroxypropyl cellulose solution 2 were mixed.
- a binding solution 2 was obtained.
- 3125 g of mantole and 450 g of low-substituted hydroxypropylcellulose are uniformly mixed in a fluidized bed granulator (FD-5S, Parec) and then granulated by spraying Binder 2 in the machine. Then, the resultant was dried in a fluidized bed granulator to obtain megnoremin granules.
- FD-5S, Parec fluidized bed granulator
- the obtained two granules were crushed with a 1.5 ⁇ punching screen using a power mill crusher (P-3, Showa Chemical Machinery Works) to obtain sized powder.
- P-3 Showa Chemical Machinery Works
- 3486 g of the sized powder containing the active ingredient obtained 3486 g of the sized powder containing meglumine, 1245 g of microcrystalline cellulose and 83.0 g of magnesium stearate were added and mixed with a tumbler mixer (TM-60S, Showa Chemical Machinery Works). And granules for tableting.
- the obtained granules are tableted with a rotary tableting machine (Collect 12HUK: Kikusui Seisakusho) using a punch with a long diameter of 8.5 mm and a short diameter of 5 mm at a weight of 1001 ⁇ (tablet pressure 41 ⁇ ] ⁇ / punch. )
- a rotary tableting machine Collect 12HUK: Kikusui Seisakusho
- Formulation (composition per tablet): 1) Compound A 0.3 m.g
- the composition of the present invention comprises a low molecular weight active substance whose stability is impaired by the influence of an aldehyde, and an amine structure, in a composition in which an aldehyde-like substance can be supplied, such as a pharmaceutical product, cosmetics, or a hair treatment product.
- an aldehyde-like substance such as a pharmaceutical product, cosmetics, or a hair treatment product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003301654A AU2003301654A1 (en) | 2002-10-22 | 2003-10-21 | Stabilized composition |
CA002502825A CA2502825A1 (en) | 2002-10-22 | 2003-10-21 | Stabilized composition |
EP03756722A EP1559433A4 (en) | 2002-10-22 | 2003-10-21 | STABILIZED COMPOSITION |
JP2005501570A JPWO2004037293A1 (ja) | 2002-10-22 | 2003-10-21 | 安定化組成物 |
US10/531,915 US20050267222A1 (en) | 2002-10-22 | 2003-10-21 | Stabilized composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-307241 | 2002-10-22 | ||
JP2002307241 | 2002-10-22 | ||
JP2003-186591 | 2003-06-30 | ||
JP2003186591 | 2003-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004037293A1 true WO2004037293A1 (ja) | 2004-05-06 |
Family
ID=32179077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013419 WO2004037293A1 (ja) | 2002-10-22 | 2003-10-21 | 安定化組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050267222A1 (ja) |
EP (1) | EP1559433A4 (ja) |
JP (1) | JPWO2004037293A1 (ja) |
AU (1) | AU2003301654A1 (ja) |
CA (1) | CA2502825A1 (ja) |
WO (1) | WO2004037293A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006132363A1 (ja) * | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
JP2008534522A (ja) * | 2005-03-30 | 2008-08-28 | ジェンファーム インク | 医薬組成物のための複合ステップ製造方法 |
JP2008281539A (ja) * | 2007-05-14 | 2008-11-20 | Toyo Seiyaku Kasei Kk | アルデヒド系消毒剤の有効濃度判定用固形剤型インディケータ |
EP1803447B1 (en) * | 2004-09-09 | 2009-07-22 | Psicofarma, S.A. De C.V. | Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment |
JP2009534371A (ja) * | 2006-04-21 | 2009-09-24 | ザ プロクター アンド ギャンブル カンパニー | 呼吸器疾患の治療のために有用な組成物及び方法 |
JP2009534372A (ja) * | 2006-04-28 | 2009-09-24 | ザ プロクター アンド ギャンブル カンパニー | フェニレフリン及びアセトアミノフェンを含む液体組成物、並びに呼吸器疾患の治療のためのこれらの使用 |
JP2009535305A (ja) * | 2006-04-21 | 2009-10-01 | ザ プロクター アンド ギャンブル カンパニー | 呼吸器疾患の治療に有用な組成物及びキット |
JP2009543777A (ja) * | 2006-07-14 | 2009-12-10 | ワイス | 安定性を増強したフェニレフリン液体組成物 |
JP2010229076A (ja) * | 2009-03-27 | 2010-10-14 | Kyorin Pharmaceut Co Ltd | イミダフェナシン含有口腔内崩壊錠 |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
JP5918895B1 (ja) * | 2015-05-21 | 2016-05-18 | 富士カプセル株式会社 | ナルフラフィン塩酸塩含有カプセル製剤 |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
JP2018504369A (ja) * | 2014-12-04 | 2018-02-15 | ジーイー・ヘルスケア・リミテッド | 放射性医薬品からアセトアルデヒドを除去する方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE414105T1 (de) * | 2002-10-11 | 2008-11-15 | Chugai Pharmaceutical Co Ltd | Zelltod-induzierender wirkstoff |
TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
AU2004297109A1 (en) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducing agent |
US20080206229A1 (en) * | 2003-12-12 | 2008-08-28 | Koichiro Ono | Modified Antibodies Recognizing Receptor Trimers or Higher Multimers |
WO2005056602A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | アゴニスト活性を有する改変抗体のスクリーニング方法 |
US20080274110A1 (en) * | 2004-04-09 | 2008-11-06 | Shuji Ozaki | Cell Death-Inducing Agents |
EP1927367A4 (en) * | 2005-05-18 | 2009-08-12 | Univ Tokushima | NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY |
AR061986A1 (es) * | 2006-07-13 | 2008-08-10 | Chugai Pharmaceutical Co Ltd | Agentes inductores de muerte celular |
CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
SI2603232T1 (sl) | 2010-08-11 | 2020-03-31 | Ironwood Pharmaceuticals, Inc. | Stabilne formulacije linaklotida |
WO2015144804A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
CN109444438B (zh) * | 2018-10-25 | 2022-03-15 | 宁波瑞源生物科技有限公司 | 一种用于aptt检测试剂的稳定剂及aptt检测试剂 |
CN116250538A (zh) * | 2021-12-09 | 2023-06-13 | 沈阳中化农药化工研发有限公司 | 一种含稳定剂的杀虫组合物及制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60161925A (ja) * | 1984-02-02 | 1985-08-23 | Sanwa Kagaku Kenkyusho:Kk | 安定なカリジノゲナーゼ打錠製剤の製法 |
JPS60233011A (ja) * | 1984-05-04 | 1985-11-19 | Ajinomoto Co Inc | パツプ剤 |
JPH01279843A (ja) * | 1988-04-28 | 1989-11-10 | Yasuo Moritsugu | 凍結乾燥a型肝炎ワクチン |
WO1995001096A1 (en) * | 1993-06-29 | 1995-01-12 | Shapiro Howard K | Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology |
WO1996014365A2 (en) * | 1994-11-07 | 1996-05-17 | Warner-Lambert Company | Process for stabilizing gelatin products |
JPH08291071A (ja) * | 1995-04-20 | 1996-11-05 | Yamanouchi Pharmaceut Co Ltd | ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法 |
WO2001028571A1 (fr) * | 1999-10-22 | 2001-04-26 | Nippi, Incorporated | Preparations stables pour le traitement des escarres, des ulceres de la peau et des blessures |
WO2001043762A2 (en) * | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | Polypeptide compositions with improved stability |
WO2001074397A1 (fr) * | 2000-03-31 | 2001-10-11 | Kirin Beer Kabushiki Kaisha | Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree |
WO2002032402A1 (en) * | 2000-10-13 | 2002-04-25 | Cambridge Biostability Ltd. | Composition and method for stable injectable liquids |
JP2003055263A (ja) * | 2001-08-20 | 2003-02-26 | Fuji Capsule Kk | 軟カプセル剤充填用組成物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2847975A1 (de) * | 1978-11-04 | 1980-05-14 | Merck Patent Gmbh | Verfahren zur bindung von freiem formaldehyd in pharmazeutischen und kosmetischen zubereitungen |
JP2790659B2 (ja) * | 1989-06-30 | 1998-08-27 | 帝国臓器製薬株式会社 | ゼラチンカプセル剤 |
US5130255A (en) * | 1990-12-13 | 1992-07-14 | Genentech, Inc. | Process for preparing storage stable pharmaceuticals |
US5192561A (en) * | 1991-09-19 | 1993-03-09 | Wm. Wrigley Jr. Company | Aspartame stability in chewing gum using an acid gelatin system |
US5998483A (en) * | 1991-09-20 | 1999-12-07 | Camiener; Gerald W. | Glyoxal-containing preservative compositions |
DE4141351A1 (de) * | 1991-12-14 | 1993-06-17 | Basf Ag | Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung |
US5348666A (en) * | 1993-03-31 | 1994-09-20 | Union Carbide Chemicals & Plastics Technology Corporation | Method for stabilizing glutaraldehyde in aqueous systems |
AU676315B2 (en) * | 1993-06-30 | 1997-03-06 | Takeda Chemical Industries Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
JP3203108B2 (ja) * | 1993-08-26 | 2001-08-27 | 協和メデックス株式会社 | グルコース−6−リン酸デヒドロゲナーゼの安定化方法 |
WO1997033568A1 (en) * | 1996-03-12 | 1997-09-18 | Novartis Ag | Filled gelatin capsules having a reduced degree of cross-linking |
US6190701B1 (en) * | 1999-03-17 | 2001-02-20 | Peter M. Ronai | Composition and method for stable injectable liquids |
US6255331B1 (en) * | 1999-09-14 | 2001-07-03 | Rohm And Haas Company | Stable biocidal compositions |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
MXPA02004666A (es) * | 1999-11-12 | 2003-06-24 | Fibrogen Inc | Gelatinas recombinantes. |
US6540991B2 (en) * | 2001-04-06 | 2003-04-01 | 3M Innovative Properties Company | Stabilized active materials |
WO2003087335A2 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
ES2355723T3 (es) * | 2002-09-11 | 2011-03-30 | Elan Pharma International Limited | Composiciones de agente activo en nanopartículas estabilizadas en gel. |
-
2003
- 2003-10-21 JP JP2005501570A patent/JPWO2004037293A1/ja active Pending
- 2003-10-21 WO PCT/JP2003/013419 patent/WO2004037293A1/ja active Application Filing
- 2003-10-21 CA CA002502825A patent/CA2502825A1/en not_active Abandoned
- 2003-10-21 US US10/531,915 patent/US20050267222A1/en not_active Abandoned
- 2003-10-21 EP EP03756722A patent/EP1559433A4/en not_active Withdrawn
- 2003-10-21 AU AU2003301654A patent/AU2003301654A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60161925A (ja) * | 1984-02-02 | 1985-08-23 | Sanwa Kagaku Kenkyusho:Kk | 安定なカリジノゲナーゼ打錠製剤の製法 |
JPS60233011A (ja) * | 1984-05-04 | 1985-11-19 | Ajinomoto Co Inc | パツプ剤 |
JPH01279843A (ja) * | 1988-04-28 | 1989-11-10 | Yasuo Moritsugu | 凍結乾燥a型肝炎ワクチン |
WO1995001096A1 (en) * | 1993-06-29 | 1995-01-12 | Shapiro Howard K | Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology |
WO1996014365A2 (en) * | 1994-11-07 | 1996-05-17 | Warner-Lambert Company | Process for stabilizing gelatin products |
JPH08291071A (ja) * | 1995-04-20 | 1996-11-05 | Yamanouchi Pharmaceut Co Ltd | ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法 |
WO2001028571A1 (fr) * | 1999-10-22 | 2001-04-26 | Nippi, Incorporated | Preparations stables pour le traitement des escarres, des ulceres de la peau et des blessures |
WO2001043762A2 (en) * | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | Polypeptide compositions with improved stability |
WO2001074397A1 (fr) * | 2000-03-31 | 2001-10-11 | Kirin Beer Kabushiki Kaisha | Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree |
WO2002032402A1 (en) * | 2000-10-13 | 2002-04-25 | Cambridge Biostability Ltd. | Composition and method for stable injectable liquids |
JP2003055263A (ja) * | 2001-08-20 | 2003-02-26 | Fuji Capsule Kk | 軟カプセル剤充填用組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1559433A4 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1803447B1 (en) * | 2004-09-09 | 2009-07-22 | Psicofarma, S.A. De C.V. | Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment |
JP4814885B2 (ja) * | 2004-09-09 | 2011-11-16 | サイコファルマ,エッセ.エ.デ セ.ウヴェ. | ヒドララジン持続放出用医薬組成物および該組成物を含む癌治療薬 |
JP2008534522A (ja) * | 2005-03-30 | 2008-08-28 | ジェンファーム インク | 医薬組成物のための複合ステップ製造方法 |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
AU2006256041B2 (en) * | 2005-06-10 | 2012-03-29 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9777066B2 (en) | 2005-06-10 | 2017-10-03 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
WO2006132363A1 (ja) * | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
KR101367544B1 (ko) * | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
JP2009535305A (ja) * | 2006-04-21 | 2009-10-01 | ザ プロクター アンド ギャンブル カンパニー | 呼吸器疾患の治療に有用な組成物及びキット |
JP2009534371A (ja) * | 2006-04-21 | 2009-09-24 | ザ プロクター アンド ギャンブル カンパニー | 呼吸器疾患の治療のために有用な組成物及び方法 |
US10098873B2 (en) | 2006-04-21 | 2018-10-16 | The Procter & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
JP2009534372A (ja) * | 2006-04-28 | 2009-09-24 | ザ プロクター アンド ギャンブル カンパニー | フェニレフリン及びアセトアミノフェンを含む液体組成物、並びに呼吸器疾患の治療のためのこれらの使用 |
JP2009543777A (ja) * | 2006-07-14 | 2009-12-10 | ワイス | 安定性を増強したフェニレフリン液体組成物 |
EP2351554B1 (en) | 2006-07-14 | 2015-09-09 | Wyeth LLC | Enhanced stability phenylephrine liquid compositions |
JP2008281539A (ja) * | 2007-05-14 | 2008-11-20 | Toyo Seiyaku Kasei Kk | アルデヒド系消毒剤の有効濃度判定用固形剤型インディケータ |
JP2010229076A (ja) * | 2009-03-27 | 2010-10-14 | Kyorin Pharmaceut Co Ltd | イミダフェナシン含有口腔内崩壊錠 |
JP2018504369A (ja) * | 2014-12-04 | 2018-02-15 | ジーイー・ヘルスケア・リミテッド | 放射性医薬品からアセトアルデヒドを除去する方法 |
US10660966B2 (en) | 2014-12-04 | 2020-05-26 | Ge Healthcare Limited | Method for removing acetaldehyde |
JP2021063078A (ja) * | 2014-12-04 | 2021-04-22 | ジーイー・ヘルスケア・リミテッド | 放射性医薬品からアセトアルデヒドを除去する方法 |
US11389538B2 (en) | 2014-12-04 | 2022-07-19 | Ge Healthcare Limited | Method for removing acetaldehyde |
JP7164583B2 (ja) | 2014-12-04 | 2022-11-01 | ジーイー・ヘルスケア・リミテッド | 放射性医薬品からアセトアルデヒドを除去する方法 |
JP7379638B2 (ja) | 2014-12-04 | 2023-11-14 | ジーイー・ヘルスケア・リミテッド | 放射性医薬品からアセトアルデヒドを除去する方法 |
US11964020B2 (en) | 2014-12-04 | 2024-04-23 | Ge Healthcare Limited | Method for removing acetaldehyde |
JP5918895B1 (ja) * | 2015-05-21 | 2016-05-18 | 富士カプセル株式会社 | ナルフラフィン塩酸塩含有カプセル製剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1559433A1 (en) | 2005-08-03 |
JPWO2004037293A1 (ja) | 2006-02-23 |
EP1559433A4 (en) | 2009-11-04 |
CA2502825A1 (en) | 2004-05-06 |
AU2003301654A1 (en) | 2004-05-13 |
US20050267222A1 (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004037293A1 (ja) | 安定化組成物 | |
Narang et al. | Impact of excipient interactions on solid dosage form stability | |
TWI741106B (zh) | 葡萄糖激酶活化劑的口服製劑及其製備方法 | |
JP4995798B2 (ja) | ナテグリニド含有製剤 | |
JP2018184410A (ja) | 非晶質ダパグリフロジンを含有する製剤 | |
JP4446177B2 (ja) | 耐湿性口腔内崩壊錠の製造方法 | |
JP5490347B2 (ja) | 経口投与用製剤 | |
CA2501345A1 (en) | Gastro-retentive levodopa delivery form | |
JPH04210919A (ja) | ピモベンダン経口投与製剤 | |
RU2300368C2 (ru) | Содержащая ибупрофен композиция | |
JP2000178182A (ja) | 崩壊性組成物 | |
TW201717937A (zh) | 含有芳基烷基胺化合物之醫藥組合物 | |
JPH0813736B2 (ja) | 単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法 | |
JP2000178184A (ja) | 粒状組成物、錠剤及び粒状組成物の製造方法 | |
JP2013216701A (ja) | 経口投与用製剤 | |
JP2019023246A (ja) | 有効成分の放出性が向上した医薬調製物における賦形剤としての炭酸水酸化マグネシウム | |
JP2005281178A (ja) | パンテチン含有粒状物 | |
WO2020111089A1 (ja) | 医薬組成物 | |
CN110151721B (zh) | 一种含有阿托伐他汀钙的片剂及其制备方法 | |
WO2018079570A1 (ja) | 安定な医薬組成物 | |
WO2004028523A1 (ja) | パンテチン含有粒状物 | |
JP2022151564A (ja) | 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤 | |
RU2188019C1 (ru) | Фармацевтическая композиция, обладающая противогрибковой активностью, и способ ее получения | |
MX2007015359A (es) | Preparacion farmaceutica solida que contiene (r)-(-)-2-[5-(4- fluorofenil)-3-piridilmetilaminometil]-cromano. | |
WO2005002569A1 (fr) | Preparation de ranitidine en granules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2502825 Country of ref document: CA Ref document number: 10531915 Country of ref document: US Ref document number: 2005501570 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003756722 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003756722 Country of ref document: EP |